The Ion has tapped DivInc. as a partner. Courtesy of Rice University

Houston is ranked the No. 1 diverse city in the nation, and a local organization has forged a new partnership to make sure that diversity is represented within the city's innovation ecosystem.

The Ion, an innovation hub currently rising in Midtown Sears Building, and DivInc, a Texas nonprofit, have agreed to partner to advance diversity among Houston entrepreneurs. It's Austin-based DivInc's first Houston initiative, according to a news release.

"Our experience equipping diverse entrepreneurs with strategies to create exceptional companies, coupled with the Ion's enthusiasm and thoughtful approach to building an inclusive space where entrepreneurs from all walks of life can thrive is a winning combination," says Preston L. James, founder and CEO of DivInc, in the release.

"No matter where they are in their entrepreneur journey, we want all Houstonians to know DivInc is here to help you achieve your biggest dreams."

Since its founding in 2016, DivInc has worked to provide over 60 founders and more than 50 tech companies with resources and support for growth. Locally, DivInc is already working on programming to extend its reach to Houston entrepreneurs, including a kick-off event at The Ion on Tuesday, March 3, at 5:30 pm.

"As The Ion looked for a partner to provide best practices and resources to our local business communities and leaders that have historically been overlooked, we knew our partner needed to be ambitious, thoughtful and encouraging, but also have a record of success and experience working shoulder-to-shoulder with entrepreneurs," says Deanea LeFlore, senior director of The Ion, in the release.

"Our efforts and relationship with DivInc will do just that. We can't wait to help our stakeholders take their businesses to new heights and further demonstrate Houston is the best city in America for diverse entrepreneurs to thrive."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.